Recall Forensics

Recall Forensics: The A&P Creations X10 / biQ-FEL Tainted-Supplement Recall — the validation failure behind it

Team ValidLeaf · October 2026 · 6 min read

Recall Forensics is our series tracing real dietary supplement recalls and FDA enforcement actions to the specific validation gap behind them. Every fact comes from public regulator records or trade-press reporting of those records — no speculation, no invented causes. This case is about two "natural enhancement" liquids that sold on Amazon and Walmart.com for roughly eighteen months before FDA laboratory testing found prescription drugs inside — and the company whose name appears on the recall never manufactured either product.

What happened

On September 14, 2026, A&P Creations LLC of Clermont, Florida, announced a nationwide recall of two dietary supplement products — X10 Natural Enhancement Supplement and biQ-FEL — after FDA laboratory testing found both contained undeclared sildenafil and tadalafil, the prescription-only active ingredients in Viagra and Cialis. The FDA published the company's announcements the following day, September 15 (FDA MedWatch; Men's Fitness).

The details matter for anyone who sells supplements they don't make. X10 is a liquid sold in a red-and-gold box of seven 15 mL lightning-bolt-shaped sachets, UPC 7708075247094, with Spanish-language packaging describing it as a "Bebida energizante" (energy beverage). Three lots were recalled: F090824LN16, F170325LN19, and F300326LN28, with expiration dates running from August 2026 through March 2028. biQ-FEL is a 500 mL bottle labeled in Spanish (including "Sabor artificial Hierbabuena"); two lots were recalled, biQ-f001-06-25 (expiring May 2027) and biQ-003-01-26 (expiring January 2028, UPC 7709799120663) (whatsissue.com).

Both products were sold through Amazon, Walmart.com, and the company's own site, naturefuel.us, from December 15, 2024 through June 11, 2026 — roughly eighteen months of marketplace distribution. The health risk is not theoretical: sildenafil and tadalafil are approved for use only under a licensed health care professional's supervision, and both can interact with nitrates — prescription drugs like nitroglycerin, common among people with diabetes, high blood pressure, high cholesterol, or heart disease — to drive blood pressure to dangerous levels. A&P Creations reported no adverse events as of September 14 and said it is notifying buyers through Amazon's and Walmart's systems. Consumers holding either product were told to stop using it and destroy or dispose of it (FDA MedWatch).

Then there is the sentence that makes this case a study in validation: A&P Creations says it bought and resold the products as finished goods and did not manufacture them (Men's Fitness). The recall notice carries its name anyway.

An honesty note, because we hold ourselves to it: public reporting does not establish where the sildenafil and tadalafil entered the product — whether the upstream maker spiked the formulas deliberately, or a contaminated component flowed in from further up the chain. The exact mechanism has not been publicly detailed. The lesson below applies in either case.

The validation gap: identity verification of finished goods you didn't manufacture

This is the private-label economy's blind spot. A distributor buys finished bottles, lists them on major marketplaces, and builds revenue on someone else's manufacturing — often with no quality system standing between the upstream maker's choices and the consumer. In this model, "we didn't make it" feels like a shield. On the recall notice, it is the opposite: the brand owner's name is the one consumers see, the press prints, and the FDA posts.

Dietary supplement cGMPs under 21 CFR Part 111 put identity and purity verification at the center of compliant manufacturing — components must be verified against specifications before they go into a product, and finished products must meet their specifications. When you sell finished goods made by someone else, you inherit that duty for the product you put into commerce. The controls that would have caught this are the ones a reseller-style operation almost never has:

• Qualify the finished-goods maker like a supplier — because they are one. A distributor buying finished product still needs an approved-supplier program covering the upstream manufacturer: who they are, what quality system they run, and whether they have the right and the data to show it. An unsigned invoice is not a quality agreement.
• Incoming identity verification, even for finished bottles. Under cGMP expectations, what you sell must match what the label claims. A distributor that screens incoming lots for identity — including screening for the actives the category is notorious for — converts the supplier's claim into evidence. "Natural enhancement" products are the exact category the FDA has long flagged as most likely to hide prescription drugs; that risk profile should have driven testing, not trust.
• Don't outsource your quality responsibility with your manufacturing. Contracting out production transfers work, not accountability. If your company name sits on the recall, the failure happened inside your quality system — the part of it that was supposed to verify what you sell.
• Surveillance testing on a cadence, not once. The products sold for about eighteen months before FDA labs caught them. Enforcement sampling is sparse; a distributor doing periodic surveillance on its own finished goods is not duplicating the regulator — it is substituting for an inspection that may never come.

This case sits in the same family as our Niwali tejocote teardown — identity failure inside a bottle — but the angle is different. There, the wrong plant went in at the ingredient level. Here, nobody in the selling chain ever checked what was in the bottle at all. And unlike the warning-letter enforcement pattern we've traced before, there was no manufacturer inspection building the case: the distributor discovered its exposure only when the regulator's lab results arrived.

How a GMP Readiness Assessment catches it

This is exactly the distributor-shaped failure a GMP Readiness Assessment is built to surface before the recall does. Over four weeks, it reviews your supplement operation for:

• Finished-goods supplier qualification — are the contract makers behind your products approved suppliers with quality agreements and audit history, or just invoices?
• Incoming verification specs — do your purchased finished goods carry identity and purity specifications with testing, or does a pallet get a visual once-over and a warehouse slot?
• Category-risk testing — where your testing program targets the adulteration risks of the categories you sell, and where a tainted-products blind spot sits open.
• Recall readiness — can you trace every lot to its customers and its upstream maker the way the regulator will demand, on the day the lab results arrive?

It closes with a gap assessment, a remediation roadmap, and starter specification and supplier-qualification templates — so the fix starts before the FDA's lab report does.